Had they included just one of Tony Hoare’s achievements, many scientific careers would be considered prestigious enough. His had a long list, unfortunately closed by his passing away at the age of 92 ...

Recursive self improvement is the key to solving intelligence. Human intelligence is built on our ability to characterize the ...

The rapid advancement of Artificial Intelligence has moved us from simple chatbots to autonomous agents. These agents do not just answer questions; they plan, use tools, and execute tasks with minimal ...

Recursion Pharmaceuticals (RXRX) has drawn attention after recent trading, with the share price closing at US$3.42 and short term returns showing pressure over the past week, month and past 3 months.

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

The human faculty to generate an infinite set of structured expressions in language, present in most cultures and normal ontogeny, is the most substantial evidence of the human capacity for recursion.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

I now rate Recursion Pharma a sell due to disappointing recent trial updates and uncertain future prospects. REC-4881's phase 2 TUPELO trial showed mixed results, with one patient experiencing a ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...